233 related articles for article (PubMed ID: 27769779)
1. Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Gowda R; Sharma A; Robertson GP
Cancer Lett; 2017 Jan; 385():243-250. PubMed ID: 27769779
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.
Gowda R; Kardos G; Sharma A; Singh S; Robertson GP
Mol Cancer Ther; 2017 Mar; 16(3):440-452. PubMed ID: 28003325
[TBL] [Abstract][Full Text] [Related]
3. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells.
Wang CC; Chiang YM; Sung SC; Hsu YL; Chang JK; Kuo PL
Cancer Lett; 2008 Jan; 259(1):82-98. PubMed ID: 18023967
[TBL] [Abstract][Full Text] [Related]
4. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling.
Cao YY; Yu J; Liu TT; Yang KX; Yang LY; Chen Q; Shi F; Hao JJ; Cai Y; Wang MR; Lu WH; Zhang Y
Cell Death Dis; 2018 Jan; 9(2):17. PubMed ID: 29339720
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
6. ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Liu J; Wu J; Zhou L; Pan C; Zhou Y; Du W; Chen JM; Zhu X; Shen J; Chen S; Liu RY; Huang W
Oncotarget; 2015 Aug; 6(25):21341-52. PubMed ID: 26050198
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.
Gowda R; Madhunapantula SV; Desai D; Amin S; Robertson GP
Mol Cancer Ther; 2013 Jan; 12(1):3-15. PubMed ID: 23112250
[TBL] [Abstract][Full Text] [Related]
8. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
9. Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.
Kuzu OF; Gowda R; Sharma A; Noory MA; Kardos G; Madhunapantula SV; Drabick JJ; Robertson GP
Cancer Biol Ther; 2018 Jan; 19(1):53-62. PubMed ID: 28853983
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
Lin JZ; Hameed I; Xu Z; Yu Y; Ren ZY; Zhu JG
Oncol Rep; 2018 Oct; 40(4):2242-2250. PubMed ID: 30066906
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
Zhao S; Cai J; Bian H; Gui L; Zhao F
Cancer Invest; 2009 Jul; 27(6):636-40. PubMed ID: 19387877
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Effects of Culinary Herbs and Spices on the Growth of HCA-7 Colorectal Cancer Cells and Their COX-2 Expression.
Jaksevicius A; Carew M; Mistry C; Modjtahedi H; Opara EI
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28934138
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
15. Casticin Induced Apoptosis in A375.S2 Human Melanoma Cells through the Inhibition of NF-[Formula: see text]B and Mitochondria-Dependent Pathways In Vitro and Inhibited Human Melanoma Xenografts in a Mouse Model In Vivo.
Shiue YW; Lu CC; Hsiao YP; Liao CL; Lin JP; Lai KC; Yu CC; Huang YP; Ho HC; Chung JG
Am J Chin Med; 2016; 44(3):637-61. PubMed ID: 27109154
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
17. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Zhao Y; Hao Y; Ji H; Fang Y; Guo Y; Sha W; Zhou Y; Pang X; Southerland WM; Califano JA; Gu X
Cancer Prev Res (Phila); 2010 Jun; 3(6):787-96. PubMed ID: 20501859
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines.
Bundscherer A; Hafner C; Maisch T; Becker B; Landthaler M; Vogt T
Oncol Rep; 2008 Feb; 19(2):547-53. PubMed ID: 18202806
[TBL] [Abstract][Full Text] [Related]
19. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Xu HB; Shen FM; Lv QZ
Eur J Pharmacol; 2015 Dec; 769():1-7. PubMed ID: 26407653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]